Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.
Required for US and Japanese stocks. A-shares and HK stocks work without a key.
DeepSeek R1 provides high-quality analysis at very low cost. Serper provides real-time search data for context.
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner. It also provides immunohistochemistry products including automatic antigen repair instrument and automatic immunocytochemical staining machine, as well as conversional pathology equipment. The company was founded in 2005 and is based in Guangzhou, China.
交易所：Shanghai Stock Exchange。行业板块：Healthcare。细分行业：Medical Instruments & Supplies。最新股价：¥18.9。本页提供 安必平 的 DCF 现金流折现估值、相对估值历史分位、多维财务评分与 AI 辅助分析。